Protara Therapeutics (TARA) Fundamental Analysis: Revenue, Earnings & Valuation

3.84 / 10

Netural

Fundamental health is weak (3.8/10). Strengths include cash‑to‑market value and high inventory turnover, while income‑tax‑to‑profit and revenue‑to‑market ratios lag. Overall, the balance sheet shows limited quality, supporting a cautious outlook.

Analysis Checks(6/10)

Revenue-MV

Value-0.11

Score1/3

Weight12.18%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight3.15%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight16.16%

1M Return6.74%

Gross profit margin (%)

Value41.83

Score1/3

Weight-1.15%

1M Return-0.63%

PB-ROE

Value-0.13

Score1/3

Weight13.54%

1M Return5.29%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-0.93%

1M Return-0.50%

Fixed assets turnover ratio

Value9306.28

Score3/3

Weight2.08%

1M Return1.06%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight9.35%

1M Return4.32%

Asset-MV

Value-0.55

Score2/3

Weight31.25%

1M Return12.22%

Cash-MV

Value0.02

Score2/3

Weight14.36%

1M Return5.94%

Is TARA undervalued or overvalued?

TARA scores 3.84/10 on fundamentals and holds a Fair valuation at present. Backed by its -31.60% ROE, 0.00% net margin, -4.75 P/E ratio, 1.39 P/B ratio, and 38.25% earnings growth, these metrics solidify its Netural investment rating.